BD MediFlupentixol + Melitracen
Combined anxiolytics & anti-depressant drugs
Brands & Prices (77)
📋 Indications & Uses Dosage & Administration⚠️ Contraindications⚡ Side Effects & Adverse Reactions🛡️ Warnings & Precautions🔬 Pharmacology & Mechanism
Brand Formulations & Prices
77 brands sorted by unit price
Pentixol
Penxit
Amilax
Zenxit
Aenixit
Banxyt
Femixit
Frexit
Henxit
Stimo
Tensa
Exuten
Amelex
Anotic
Anxitol
Exzilor
Femanol
Flumetra
Flupenxit
Inspra
Lumexit
Melit
Relux
Metflu
Neoxit
Depresil
Anfree
Angenta
Antison
Antixit
Anxino
Anzet
Benzit
Dam
Danxit
Deleta
Denazit
Dexit
Diconten
Dinxi
Dormir
Eraxit
FMR
Flutracen
Frenxit
Fulrest
Joyxit
Melanxit
Meltix
Melxit
Mixit
Noanxit
Norxit
Penticin
Radex
Remood
Renxit
Sensit
Srenxit-M
Tenaxit
Tensicon
Thenxet
Tixocin
Tixol
Unzip
Valium Plus
Xolmel
Anxicon
Leanxit
U4
Anxit
Fluxit
Melixol
Xolitra
Adelax
Flunxit
Fulimet
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesFlupentixol and Melitracen tablet is indicated in-
Anxiety
Depression
Apathy
Psychogenic depression.
Depressive neurosses.
Masked depression.
Psychosomatic affections accompanied by anxiety and apathy.
Menopausal depressions.
Dysphoria and depression in alcoholics and drug addicts.
Dosage & AdministrationAdults
: Usually 2 tablets orally daily in the morning and noon. In severe cases, the morning dose may be increased to 2 tablets.
Elderly patients
: 1 tablet in the morning.
Maintenance dose
: Usually 1 tablet orally in the morning. In cases of insomnia or severe restlessness, additional treatment with a sedative in the acute phase is recommended.
The immediate recovery phase after myocardial infarction.
Defects in bundle-branch conduction.
Untreated narrow-angle glaucoma.
Acute alcohol, barbiturate and opiate intoxications.
This tablet should not be given to patients who have received an MAO-inhibitor within two weeks.
Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
In the recommended doses side effects are rare. These could be transient restlessness and insomnia.
If previously the patient has been treated with tranquillizers with sedative effect these should be withdrawn gradually.
This consists of two well known and well proven compounds: flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and melitracen-a bipolar thymoleptic with activating properties in low doses. In combination the compounds render a preparation with antidepressant, anxiolytic and activating properties. Maximal serum concentration is reached in about 4 hours after oral administration of flupentixol and in about 4 hours after oral administration of melitracen. The biological half-life of flupentixol is about 35 hours and that of melitracen is about 19 hours. The combination of flupentixol and melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.